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Abstract 
There are five melanocortin receptors (MC1R-MC5R) that primarily activate the 
signaling pathway for adenylate cyclase. While both the MC3R and MC4R are 
hypothesized to be involved in regulating energy homeostasis, the MC3R functionality has 
been elusive to characterize due to the lack of MC3R-selective ligands. The melanocortin 
system has been clearly defined as a target for treating obesity or cachexia. When centrally 
delivered through intracerebroventricular administration, agonists decrease food intake, 
while antagonists increase food intake. Previous weight management therapies have 
focused on targeting the MC4R, though off-target cardiovascular effects may limit the 
clinical utility of these ligands. Therefore, obtaining a MC3R selective compound may 
allow for a weight regulation therapy that will not have the same cardiovascular liabilities.  
 
MC4R-selective ligands have been heavily investigated, however MC3R-selective 
ligands have largely gone unexplored. A mixture-based positional scan was conducted to 
generate scaffolds with MC3R selectivity. The lead compound from the study was Ac-His-
Arg-(pI)DPhe-Tic-NH2, an MC3R agonist (EC50 40nM) and an MC4R antagonist (pA2 
7.2). The scaffold reverses the sequence of arginine and phenylalanine residues in the His-
Phe-Arg-Trp conserved sequence found in endogenous melanocortin ligands. This work 
presents a follow-up study investigating the position of the phenylalanine residue in efforts 
to create a MC3R selective agonist with decreased MC4R antagonist activity.  
 
  
 
 
ii 
 
 
Acknowledgements 
 
I would like to give a special thanks to my lab mates, because without them this would not 
have been possible. Thank you to my committee members, Dr. Johnson, Dr. Ambrose, Dr. 
Pomerantz, and Dr. Doran, for their feedback and support. Special thanks to my advisor, 
Dr. Carrie Haskell-Luevano for her guidance and encouragement. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
Table of Contents 
 
Acknowledgements…………………………………………….ii 
List of Tables ……………………………………………..........iv 
List of Figures ………………………………………………….v 
 
Exploring mMC3R Activity through SAR of the DPhe position in 
the Ac-His-Arg-DPhe-Tic-NH2 
Introduction…………………………………………………….Pg. 1 
Experimental…………………………………………………...Pg. 4 
Results……………………………………………………….....Pg. 8 
Discussion and Conclusion………………………………….....Pg. 12 
Bibliography…………………………………………………....Pg. 27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
List of Tables 
 
Table 1. Tetrapeptide Characterization……………………………………..Pg. 17 
 
Table 2.  Agonist and Antagonist Activity of DPhe Substitutions at the mMC3R, 
mMC4R and mMC5R ……………………………………………………....Pg. 18 
Table 3.  Agonist Activity of DPhe Substitutions at the mMC1R……………......Pg. 20 
Table 4. Calculated Properties of Tetrapeptides…………………………………....Pg. 21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
List of Figures 
 
Figure 1. Scaffold of peptide library ………………………………………....Pg 22 
Figure 2. Illustration of agonist activity observed in mouse melanocortin-3 
receptor………………………………………………………………………...Pg 23 
Figure 3. Illustration of agonist activity observed in mouse melanocortin-4 
receptor………………………………………………………………………...Pg 24 
Figure 4. Illustration of antagonist activity observed at the mouse melanocortin-4 
receptor from the most potent-MC3R agonists………………………………..Pg 25 
Figure 5. Illustration of antagonist activity observed at the mouse melanocortin-4 
receptor compounds 4, 5, 7…………………………………………………....Pg 26 
Figure 6. Electrostatic Potentials calculated with Maestro……………..…….Pg 27 
Figure 7. A scatterplot showing the potential trend between partition coefficient of 
octenol over water and mMC3R EC50 values……………………………...….Pg 28 
 
 
1 
 
 
Introduction 
 
The melanocortin receptor system contains five subtypes labeled MC1R through MC5R, 
which belong to the class-A family of rhodopsin-like G-protein coupled receptors1-6. These 
receptors primarily signal through the Gαs subunit, increasing production of cyclic adenosine 
monophosphate (cAMP)1-6. The MC1R is primarily involved in regulation of skin pigmentation1, 6. 
The MC2R is only activated by adrenocorticotropic hormone (ACTH) and is implicated in 
steroidogenesis1. Both the MC3R and MC4R contribute to the regulation of energy homeostasis, 
which have made them targets for weight regulation therapies4, 5, 7-10. Several single nucleotide 
polymorphisms (SNPs) in the MC4R11, and double variants12 as well as mutations in the MC3R 
have been associated with the onset of severe obesity13. The MC5R functionality in humans is still 
unknown, but it is known to affect the exocrine gland function in mice3, 14. 
Endogenous agonists are derived from the proopiomelanocortin (POMC) gene and include 
α-, β-, and γ-melanocortin stimulating hormone (MSH) and adrenocorticotropic hormone (ACTH). 
The only agonist to stimulate all five receptor subtypes is ACTH; α-, β-, γ-MSH stimulate all known 
receptors except the MC2R2, 15. The His-Phe-Arg-Trp motif has been found to be the minimum 
sequence of endogenous agonists necessary for melanocortin activation16-18. The melanocortin 
system contains two naturally occurring antagonists, agouti-signaling protein (ASP), and agouti-
related protein (AGRP). The antagonists inhibit receptor function at the MC1, MC3 and MC4 
receptors19-21. Further studies on AGRP identified the Arg-Phe-Phe motif, as critical for antagonist 
pharmacology22.  
Targeting the MC3R/MC4R can lead to development of treatments for metabolic diseases 
such as obesity, anorexia, and cachexia. When administrated through intracerebroventricular 
injection (ICV), agonists that are nonselective for the MC3R and MC4R result in decreased food 
intake23. When an endogenous antagonist such as AGRP is administrated in mice it has orexigenic 
effects, or increased appetite, which can last upward of seven days24. While both receptors have a 
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role in energy homeostasis, the differences in phenotype of knockout mice suggest that these roles 
are nonredundant. The MC4R knockout models show hyperphagia, they gain fat mass, and 
experience both weight and length gains compared to wild type mice25. Comparatively, the MC3R 
knockout mice models exhibit increased fat mass and reduced lean mass, while maintaining similar 
body weight to wild type mice25. To further support the hypothesis of independent roles, phenotypic 
differences between the extremely obese double knockouts and the obese single knockout models 
have been observed25.  
Previous clinical trials treating obesity with MC4R drugs and follow up studies reported 
the side effects of hypertension and induced penile erection26-30. Many studies have attempted to 
determine how the melanocortin receptors and blood pressure are linked27, 29, 31. Some evidence 
indicates that the cardiovascular side effects seen are moderated primarily through the MC4R 
pathway, with very little contributions from the MC3R pathway27. This has been tested by central 
administration of α-MSH and γ-MSH, which are more selective for the MC4R and MC3R 
respectively27. When ICV injections of α-MSH are given, the elevated blood pressure seen in wild 
type mice is not seen in MC4R deficient mice27. The γ-MSH contributions to elevated blood 
pressure have been thought to be independent of MC3R activity27. However, current clinical trials 
of the peptide Setmelanotid (Ac-Arg-c[Cys-D-Ala-His-D-Phe-Arg-Trp-Cys]-NH2), which targets 
the MC4R, have seen no indication of the adverse cardiovascular side effects32. Further exploring 
the mechanistic differences between the MC3R and MC4R, with compounds of different 
pharmacological profiles can help in the discovery of weight management therapies that do not 
have adverse cardiovascular side-effects.  
While MC4R-selective agonists have been well studied as possible treatments for 
metabolic disease, MC3R-selective targets are. Previously reported selective compounds for the 
MC3R over the MC4R, have primarily been analogues of the endogenous ligands α- and γ-MSH33-
36. In hopes of finding scaffolds with more drug-like properties, a mixture-based positional scan 
was previously used to rapidly scan for new scaffolds with unique pharmacology37, 38. Mixture-
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based positional scans are a method used to efficiently and systematically explore chemical space39, 
40. In mixture-based positional scans, multiple compounds are assayed in one well, each of the 
compounds in the well share the same amino acid residue in a single position. The compounds that 
are in active mixtures can be synthesized and tested individually. Previously, mixture-based 
positional scanning has successfully been used to identify tetrapeptides that rescued functionality 
in human MC4R containing SNPs41, and tetrapeptides with unique pharmacology profiles38. 
Amongst the new scaffolds discovered was one of particular interest, Ac-His-Arg-(pI)DPhe-Tic-
NH2, a MC3R agonist (EC50 = 40nM) and a MC4R antagonist (pA2 = 7.0)37. This scaffold reverses 
the sequence of arginine and phenylalanine residues in the His-Phe-Arg-Trp conserved sequence 
found in endogenous melanocortin ligands37.  
As compared to the MC3R agonist and MC4R antagonist profile seen by Ac-His-Arg-
(pI)DPhe-Tic-NH2, the tetrapeptide Ac-His-(pI)DPhe-Arg-Trp-NH2 expresses partial 
agonist/antagonist pharmacology at the MC3R and is a full agonist at the MC4R37. Previous SAR 
centered around substitutions of the DPhe residues have been shown that this residue is critical in 
determining if melanocortin ligands exhibit MC3R or MC4R antagonism42. When DPhe was 
replaced with bulkier residues, DNal(2’) and (pI)DPhe, in the synthetic agonist MTII (Ac-Nle-
c[Asp-His-DPhe-Arg-Trp-Lys]-NH2), potent synthetic MC3R/MC4R antagonists were created42. 
Similarly, exploring substitutions on the DPhe residue in Ac-His-DPhe-Arg-Trp-NH2 sequence 
showed that the DPhe residue was extremely important in switching the mMC3R functionality from 
an agonist to an antagonist37. Due to the importance of DPhe in the pharmacological profile of 
previous melanocortin ligands, it was hypothesized that the (pI)DPhe position in Ac-His-Arg-
(pI)DPhe-Tic-NH2 could be important to the selectivity of agonist activity in the MC3R receptor 
when compared with MC4R activity.  
Herein, we present a SAR that investigates physicochemical properties responsible for the 
selectivity of the mMC3R agonism over mMC4R activity. The creation of an MC3R selective 
agonist with decreased agonist and antagonist activity at the MC4R would allow for a chance to 
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more effectively probe the activity of the MC3R in vivo and to develop MC3R selective 
therapeutics.  
Experimental  
Synthesis: 
  Peptides were synthesized using standard solid-phase fluorenyl-9-methyloxycarbonyl 
(Fmoc) methodology43, 44. Couplings were performed using a CEM Discover SPS microwave 
peptide synthesizer. The 4-(2’,4’-dimethoxyphenyl-Fmoc-aminomethyl)phenoxacetyl-MBHA 
resin [Rink-amide-MBHA (100-200 mesh), 0.66 mequiv/g substitution], 2-(1H-benzotriazol-1-yl)-
1,1,3,3,-tetramethyluronium hexafluorophosphate (HBTU), and the listed Fmoc-protected amino 
acids [Fmoc-His(Trt), Fmoc-Arg(Pbf), Fmoc-(pF)DPhe, and Fmoc-(pCl)DPhe] were purchased 
from Peptides International (Louisville, KY, USA).  The Fmoc-(pBr)DPhe, Fmoc-(3,4-diCl)DPhe, 
Fmoc-(pCN)DPhe, Fmoc-(pMe)DPhe, Fmoc-p(NH2)DPhe(Boc), Fmoc-(pBz)-DPhe, and Fmoc-
(4-tBu)DPhe were acquired from BACHEM (San Carlos, CA, USA). Fmoc-(pI)DPhe was procured 
from Alfa Aesar (Tewksbury, MA,USA). Fmoc-(pCF3)DPhe, and Fmoc-(3-Cl)DPhe was bought 
from Chem Cruz (Dallas, TX, USA).  Fmoc-D-4,4’-Biphenylalanine and Fmoc-D-1,2,3,4-
tetrahydroisoquinoline-3-carboxylic acid (Tic) were purchased from Synth Tech (Albony, OR, 
USA). Fmoc-DTyr(But) was acquired from Ad. Chem (Lousville, KY, USA). The 
triisopropylsilane (TIS), N,N-diisopropylethylamine (DIEA), 1,2-ethanedithiol (EDT), piperidine, 
pyridine, and TFA were purchased from Sigma-Aldrich (St. Louis, MO). Acetonitrile (MeCN), 
N,N-dimethylformamide (DMF), dichloromethane (DCM), methanol (MeOH), and acetic 
anhydride were purchased from Fisher Scientific. All reagents were ACS grade or higher and used 
without further purification. 
Peptides were synthesized from C-terminus to N-terminus on Rink-amide-MBHA resin 
(Peptides International, 0.66 mequiv/g) in a fritted polypropylene reaction vessel (25 mL CEM 
reaction vessel). Resin was swelled in DCM for at least 1 hour.  Deprotection of the Fmoc protected 
amino acids was completed using 20% piperidine in DMF at 23°C for two minutes. A second 
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aliquot of 20% piperidine was added to ensure full deprotection through the assistance of 
microwave heating (75°C, 30W, 4 min). Amide bonds were formed by adding Fmoc-amino acids, 
HBTU, and DIEA. After each deprotection or coupling, resin was washed 3-5 times with DMF and 
confirmed with either a ninhydrin45 or chloranil test46. Ninhydrin/Kaiser tests indicate the presence 
or lack of a free primary amine and chloranil tests indicate the presence or lack of a secondary 
amine. After the final peptide was added, the peptide was deprotected a final time and the N-
terminus was acetylated on resin using a 3:1 mixture of acetic anhydride:pyridine.   
 Coupling conditions for the microwave synthesizer were as follows: 3.1:3:5 amino 
acid:HBTU:DiPEA. N-terminals were acetylated using a 3:1 solution of acetic acid 
anhydride:pyridine for 30 minutes at room temperature. Peptides were cleaved in a 91:0.3:0.3:0.3 
TFA:Thioanisol:TIS:H2O mixture. The peptide KNS2-23-9 (Ac-His-Arg-DTyr-Tic-NH2) was 
cleaved in 91:0.3:0.3:0.3 TFA:EDT:TIS:H2O mixture. After cleavage, peptides were precipitated 
in 0°C chilled diethyl ether. The precipitated peptide was pelleted in a centrifuge (Sorvall Legend 
XTR) at 4000 rpm at 4°C for 4 minutes.  The peptide was washed with diethyl ether and pelleted 
at least three times before drying overnight in a desiccator. 
 The peptides were purified using RP-HPLC semipreparative chromatography in 0.1% 
TFA and H2O with a C18 reverse phase column. The collected fractions were concentrated on a 
rotary evaporator and lyophilized three times. The pure compounds were characterized analytically 
using RP-HPLC with two solvent systems. Both acetonitrile and methanol 10-90% gradients were 
run in 0.1%TFA in water for 35 min. By integrating the area under the curve at 214 nm purity was 
determined for each compound. The mass was confirmed using ESI/TOF-MS (Bruker, BioTOF II, 
University of Minnesota Department of Chemistry Mass Spectrometry Laboratory). The peptide 
library was named TaMALES, for tetrapeptide melanocortin agonist ligands to explore selectivity.  
Activity: 
β-galactosidase assay 
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The purified compounds were tested for cAMP activity using a 96-well colorimetric β-
galactosidase assay for agonist activity at the MC3R, MC4R, and MC5R and antagonist activity47 
at the MC4R. All β-galactosidase assays were conducted by Dr. Skye Doering. The melanocortin 
receptors are cloned into HEK293 cells using a pCDNA vector which was previously described38. 
Stably transfected HEK293 cells were plated with Dulbecco’s Modified Eagle Medium (DMEM), 
with 10% bovine serum and 1% penicillin-streptomycin, into a 10 cm dish and grown until 40% 
confluent. When the cells reached 40% confluency (approximately 24 h later), cells were transiently 
transfected with 4 µg of CRE-PBKS per 10 cm plate of cells using calcium phosphate48. Twenty-
four hours after the transfection, the cells were plated onto collagen treated Nunclon Delta Surface 
96-well plates (Thermo Fischer Scientific) and incubated at 37 °C at 5% CO2. Plates were 
stimulated 48 h post transfection with compounds, which were dissolved in H2O and stored at 1000 
μg/mL in -20°C. They were then incubated at 37°C with 5% CO2 for 6 hours. Compounds were 
serially diluted in assay media (1.0 mL 1% bovine serum albumin [BSA] in phosphate buffered 
saline [PBS] and 1.0 mL of 100x isobutylmethylxanthine in 98.0 mL of DMEM) to concentrations 
ranging from 10-4 and 10-10 M. Positive controls included NDP-MSH (10-6 to 10-12 M) and forskolin 
(10 µM). Plain assay media was used as a negative control. After stimulation, media was aspirated 
from the plates and 50 µL of lysis buffer (250 mM Tris-HCL pH=8.0, 740 mL of DDH2O, 10 mL 
of 10% Triton X-100 in water) was added to each well. Plates were stored at -80 °C for up to two 
weeks, until they were ready to be assayed.  
Thawed plates were assessed for protein content and assayed for activity. Protein 
concentration was determined by adding 10 µL of cell lysate to 200 µL of BioRad dye solution (1:4 
dilution with water) in a new 96-well plate. Absorbance was measured using a 96-well plate reader 
(Molecular Devices) at λ = 595 nm. In order to determine β-galactosidase activity, 40 µL of 0.5% 
BSA in PBS at 37°C, and 150 µL of the β-galactosidase substrate (60 mM Na2HPO4, 1 mM MgCl2, 
10 mM KCl,, 50 mM 2-mercaptoethanol, and 660 µM 2-nitrophenyl β-D-galactosidase) were added 
to the remaining 40 µL of cell lysate. Plates were incubated at 37°C and periodically read on the 
 
 
7 
 
96-well plate reader until the absorbance at λ = 405 nm reached approximately 1.0 relative 
absorbance units for the positive controls. Each compound was run in duplicate and three 
independent experiments were completed. All data was fitted with dose-response curves and EC50 
values that were calculated using GraphPad Prism v4.0 software.  
AlphaScreen Bioassay. 
 This bioassay was used to determine dose-response curves for compounds at the mMC1R. 
All AlphaScreen assays were conducted by Katie Freeman. The melanocortin receptors are cloned 
into HEK293 using a pCDNA vector. AlphaScreen (PerkinElmer) uses a direct measurement of 
cAMP signaling as previously described. Cells were grown in an incubator at 37°C with 5% CO2 
in cell media [Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% newborn calf serum 
(NCS) and 1% penicillin-streptomycin] in 10 cm plates to 70-95% confluency.  
 Cells were disassociated with 1 mL of 37°C Versene solution (Gibco), resuspended in 5 
mL of 37°C cell media and centrifuged (Sorvall Legend XTR centrifuge, swinging bucket rotor) at 
800 rpm for 5 min at RT. The cell pellet was resuspended in Dulbecco’s Phosphate Buffered Saline 
solution (DPBS 1x without CaCl2 or MgCl2, Gibco) warmed to 37°C. A hemocytometer was used 
to manually count the cells using 10 µL of cell mixture added to 10 µL of Trypan blue BioRad dye. 
The cells were centrifuged (800 rpm, 5 min, RT)., and the pellet was resuspended in stimulation 
buffer [Hank’s Balanced Salt Solution (HBSS 10x without NaHCO3 or phenol red, Gibco), 0.5 mM 
isobutylmehtylxanthine (IBMX), 5 mM HEPES buffer solution (1M, Gibco), and 0.1% BSA in 
Milli-Q water, pH = 7.4] to a final concentration of 10000 cells/µL. A solution of cells and anti-
cAMP acceptor beads in stimulation buffer was than prepared (1000 cells/ µL and 0.5 µg/µL 
AlphaScreen anti-cAMP acceptor beads in stimulation buffer). Each 384-well microplate 
(OptiPlate-384, PerkinElmer) contained 10 µL of the cell/acceptor bead solution along with 5 µL 
of unknown compounds. Each ligand was tested from concentrations 10-4 to 10-12 M. The plate was 
sealed and incubated at room temperature in the dark for 2 h. Controls included NDP-MSH (10-6 to 
10-12), forskolin (10-4) and the negative control, stimulation buffer.    
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 The biotinylated cAMP/streptavidin coated donor bead mixture in lysis buffer (0.5 µg/µL 
AlphaScreen donor beads and 0.62 µM AlphaScreen cAMP biotinylated tracer in a solution of 10% 
Tween-20, 5 mM HEPES, and 0.1% BSA in Milli-Q water, pH = 7.4) was prepared under green 
light. Following the initial incubation, 10 µL of the biotinylated cAMP/streptavidin donor bead 
lysis buffer was added to each well. The plate was resealed and incubated for a second 2 h period 
in the dark. Post incubation, the plates were read by an EnSpire Alpha plate reader (PerkinElmer). 
Each compound was run in duplicate and three independent experiments were completed.  
Physical Properties 
 Physical and electrostatic properties of the ligands were determined by using Maestro 
version 10.4.017 (Schrödinger, LLC, New York, NY, 2015). Charges were assigned using the 
LigPrep tool at  pH 7.4. The ligand was minimized using OPLS 2005 force field49 until there was 
a convergence energy difference of 0.0001. The Poisson-Boltzmann equation of electrostatics was 
implemented where the solvent dielectric constant ε = 80 and the dielectric constant of solute was 
ε = 10. Qikprop was used to determine Van der Waals energy, logPo/w, PSA, hydrogen bond donors, 
and hydrogen bond acceptors.  
Results 
SAR Study 
 Substituents of the DPhe residue spanning a variety of electronic and physiochemical 
properties were tested for in vitro melanocortin receptor activity in the tetrapeptide template: Ac-
His-Arg-DPhe-Tic-NH2. The compounds were manually synthesized using a CEM Discover SPS 
microwave peptide synthesizer and standard Fmoc solid-phase peptide synthesis procedure43. 
Purification of compounds was completed using semipreparative reverse phase high pressure liquid 
chromatography (Table 1). Compounds were characterized through ESI-MS, confirming the mass, 
and RP-HPLC, verifying that all ligands are > 95% pure. Compounds activity was tested at the 
mouse MC3R-MC5R using a colorimetric β-galactosidase assay that measures cAMP activity 
(Table 2)50. Table 3 summarizes the activity at the mMC1R compounds which was characterized 
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by measuring intracellular cAMP using the Amplified Luminescent Proximity Homogenous Assay 
Screen (AlphaScreen, PerkinElmer). The AlphaScreen assay was conducted on mMC1R instead of 
the B-galactosidase assay because the mMC1R cell lines tend to be more impacted by the 
transfection conditions and duration of the β-galactosidase assay in comparison to the AlphaScreen. 
The increased stress levels alter the cells cAMP production. Both the β-galactosidase and 
AlphaScreen assays used stably transfected HEK293 cells expressing the cloned melanocortin 
receptor.  
The tetrapeptide Ac-His-Arg-(p-I)DPhe-Tic-NH2 was found in a mixture based positional 
scan and contains a unique mixed pharmacology mMC3R agonist activity (EC50 = 40 nM) and 
mMC4R antagonist activity (pA2 = 7.0) 37, 38. The Ac-His-Arg-(p-I)DPhe-Tic-NH2 compound was 
used as a control and had mMC3R agonist activity (EC50 = 13 nM) and mMC4R antagonist activity 
(pA2 = 7.2). The EC50 values of the control are slightly different from literature because the current 
values were determined through measuring activity using the β-galactosidase assay at the mMC3R 
mMC4R and mMC5R, while the literature uses the AlphaScreen assay at all tested receptors. Using 
the two following compounds: Ac-His-Arg-(4,4')DBip-Tic-NH2 (1), Ac-His-Arg-DPhe(p-tBu)-
Tic-NH2 (2), were equipotent at the mMC3R (EC50 < 16 nM) to the Ac-His-Arg-(p-I)DPhe-Tic-
NH2 (Figure 2, Table 2). Any agonist EC50 values with less than three-fold difference between them 
are defined to be within experimental error. Compounds 1, and 2 were all less potent antagonists at 
the mMC4R (6.1 < pA2 < 6.8) compared to the control compound. All of the compounds have low 
nanomolar to sub-nanomolar potency at the mMC1R (Table 3) and mMC5R (Table 2). All of 
nanomolar potent mMC3R compounds showed partial agonist activity at the mMC4R (Figure 3), 
with the exception of compound 2, compound 4, and compound 7 which did not have any mMC4R 
activity at 100,000 nM (Table 2).  This shows that the modified DPhe position in the His-Arg-
(pI)DPhe-Tic scaffold can create mMC3R nanomolar agonists and mMC4R partial agonists, this 
pharmacological profile was previously seen in compounds containing the Arg-(pI)Dphe scaffold37. 
This pharmacological profile is the opposite of that seen when the DPhe position was modified in 
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the His-DPhe-Arg-Trp scaffold, which created mMC4R agonists that retained nanomolar potency 
and mMC3R partial agonists/antagonists51. This evidence supports the hypothesis that the 
switching of the DPhe and the Arg residues in His-DPhe-Arg-Trp scaffold can lead to a switch in 
selectivity between the mMC3R and the mMC4R.  
All substituted compounds were more potent than the Ac-His-Arg-DPhe-Tic-NH2 
compound (Table 2). The two compounds that were equipotent to the control were compounds 1 
and 2. Compound 1 has agonist activity at the mMC1R (EC50 = 0.8 ± 0.3 nM), mMC3R (EC50 = 14 
± 2 nM), and mMC5R (EC50 = 8.4 ± 0.6 nM). At the mMC4R, compound 1 had antagonist activity 
(pA2 = 6.1 ± 0.2) and partial agonist activity (EC50 = 600 ± 140 nM; 43% @ 100 µM). Compound 
2 has nanomolar potency at the MC1R (EC50 = 10 ± 0.3 nM), mMC3R (EC50 = 16 ± 2 nM), and the 
mMC5R (EC50 = 8.4 ± 0.6 nM). Compound 2 has antagonist activity at the mMC4R (pA2 = 6.1 ± 
0.2). Compound 2 is the most selective compound for the mMC3R over the mMC4R due to the 
fact that it has micromolar potency as an antagonist at the mMC4R and no measurable mMC4R 
agonist activity. While compounds 1 and 2 have similar activity profiles and are at least 5-fold more 
potent at the mMC3R than other substitutions, there do not share many physical properties with the 
control compound, Ac-His-Arg-(p-I)DPhe-Tic-NH2. Both (4,4’)DBip (1) and the p-tBu (2) are both  
weak electron donating groups, but 1 contains an aromatic substituent and 2 contains an aliphatic 
substituent. This is dissimilar to the p-I substituent which donates electron density through π 
bonding, but is electronegative and known to have inductive withdrawal of electrons.  
Compounds Ac-His-Arg-DPhe(p-Br)-Tic-NH2 (3), Ac-His-Arg-DPhe(p-Cl)-Tic-NH2 (6), 
Ac-His-Arg-DPhe-(3,4)diCl-Tic-NH2 (7), and Ac-His-Arg-DPhe(p-F)-Tic-NH2 (8) contained 
halogens and were chosen to explore trends in lipophilicity and electronegativity. Compound 3 has 
agonist activity at the MC1R (EC50 = 0.8 ± 0.3 nM), mMC3R (EC50 = 85 ± 20 nM), and the mMC5R  
(EC50 = 9.7 ± 0.5 nM), while having partial agonist activity at the mMC4R (230 ± 40 nM; 54% @ 
100 µM). Compound 3 was of special interest because it has measurable partial agonist activity at 
the mMC4R but no measurable antagonist activity at the mMC4R. Compound 6 has agonist activity 
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at the MC1R (EC50 = 0.95 ± 0.08 nM), mMC3R (EC50 = 140 ± 20 nM), and the mMC5R (EC50 = 
19 ± 6 nM). Compound 6 had partial agonist activity at the mMC4R (380 ± 50 nm; 67% @ 100 
µM). Compound 7 has agonist activity at mMC1R (EC50 = 0.52 ± 0.03 nM), mMC3R (EC50 = 140 
± 70 nM), and mMC5R (EC50 = 70 ± 6 nM). Antagonist activity at the mMC4R (pA2 = 6.23 ± 0.06) 
was reported for compound 7.  Agonist activity at the MC1R (EC50 = 2.2 ± 0.7 nM), mMC3R (EC50 
= 450 ± 70 nM), and the mMC5R (EC50 = 5 ± 4 nM) was seen when testing compound 8. Compound 
8 had partial agonist activity at the mMC4R (560 ± 60 nm; 69% @ 100 µM). The most efficacious 
partial agonists were in the halogen series, specifically the compounds 6 (p-F substitution) and 8 
(p-Cl substitution).  
Trends in the halogen series were explored for mMC3R and mMC4R activity. The less 
electronegative para position substitutions of iodine and bromine (3) were slightly more potent at 
the mMC3R compared to compounds with more electronegative, smaller halogen substitutions 
chlorine (6) and fluorine (8). Antagonist mMC4R activity is only seen in the Ac-His-Arg-DPhe(p-
I)-Tic-NH2.. The partial agonist activity is greater when compounds are substituted at the para 
position with chlorine and fluorine when compared to bromine and iodine (Table 2).   
In order to confirm any trends in electronegativity and lipophilicity found in the halogen 
series, activity of the p-CF3 substituted peptide (4) was compared with the p-CH3 substituted peptide 
(5). There was no significant difference between activity at any of the melanocortin receptors 
tested, except for the partial agonist activity associated with compound 5. Compound 4 has agonist 
activity at the MC1R (EC50 = 6 ± 2 nM), mMC3R (EC50 = 90 ± 30 nM), and the mMC5R  (EC50 = 
13 ± 4 nM), while having antagonist activity at the mMC4R (pA2 = 6.4 ± 0.2) . Compound 5 has 
agonist activity at the MC1R (EC50 = 1.2 ± 0.3 nM), mMC3R (EC50 = 110 ± 20 nM), and the 
mMC5R (EC50 = 14 ± 4 nM), while having antagonist activity (pA2 = 6.3 ± 0.2) and partial agonist 
activity (390 ± 90 nm; 67% @ 100 µM) at the mMC4R. 
Two compounds had micromolar activity at the mMC3R, Ac-His-Arg-DPhe(p-CN)-Tic-
NH2 (9), and Ac-His-Arg-DTyr-Tic-NH2 (10). Compound 9 showed agonist activity at the MC1R 
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(EC50 = 32 ± 3 nM), mMC3R (EC50 = 4000 ± 1000 nM), and the mMC5R  (EC50 = 500 ± 200 nM). 
Some agonist activity at the mMC4R was detected (EC50 = 29% @ 100 µM) when testing 
compound 9. Compound 10 showed agonist activity at the MC1R (EC50 = 50 ± 10 nM), mMC3R 
(EC50 = 4300 ± 800 nM), and the mMC5R (EC50 = 1200 ± 600 nM). The polar groups (OH) in DTyr 
(compound 10) and (p-CN) in compound 9 decrease the ability of the compounds to activate the 
MC1R, MC3R and MC5R by greater than 100 fold compared to Ac-His-Arg-DPhe(p-I)-Tic-NH2. 
Compound 9 and 10 lose antagonist activity compared to the low nanomolar mMC3R compounds 
(Table 2).  
The main goal of this study was to develop a probe that minimizes mMC4R activity in 
order to study mMC3R activity thoroughly. Before the positional scan for MC3R selective 
compounds that developed possible mMC3R selective compounds38, analogs of endogenous 
ligands γ2-MSH and α-MSH were studied. By increasing the selectivity of the Ac-His-Arg-DPhe(p-
I)-Tic-NH2 scaffold for the mMC3R over the mMC4R, we are developing compounds that have 
more drug-like properties than previous endogenous analogs. These compounds could be tested in 
vivo as therapies for obesity possibly without creating undesirable side effects of previous 
melanocortin therapeutics primarily targeting the MC4R.   
Discussion 
 A structure-activity relationship study was conducted by substituting (p-I)DPhe residues 
with a series of aromatic amino acids in the tetrapeptide scaffold Ac-His-Arg-(p-I)DPhe-Tic-NH2. 
This scaffold was originally investigated for its unique pharmacological profile and the fact that it 
contained a ‘Arg-(p-I)DPhe’ motif which reversed the positions of the traditional agonist ‘Phe-Arg’ 
motif seen in the endogenous agonist sequence His-Phe-Arg-Trp18. It was hypothesized that the 
(pI)DPhe position in Ac-His-Arg-(pI)DPhe-Tic-NH2 could be important to increasing agonist 
activity selective for the mMC3R receptor when compared with mMC4R. A series of mono- and 
di- substituted DPhe substituents were chosen to explore the physicochemical properties that 
contribute to selectivity of the mMC3R over the mMC4R. The tetrapeptides were characterized in 
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vitro using the stably transfected mouse MC1R, MC3R, MC4R, and MC5R in HEK293 cells (Table 
2, 3).  
Polar Group Substitutions 
 Two polar groups were incorporated into the SAR, tetrapeptide 9 and 10 which substituted 
(p-CN)DPhe and DTy into the tetrapeptide scaffold, respectively. Both peptides have similar 
pharmacological profiles at all receptors that were studied. Tetrapeptides 9 and 10 both saw 100-
fold decreased potency at the mMC3R, mMC4R, and mMC5R when compared to the Ac-His-Arg-
DPhe(p-I)-Tic-NH2 control (Figure 2C). Potency at the MC1R also decreased when compared to 
the controls, by 40 to 63-fold, however both compound 9 and 10 were about 15-fold more potent 
at the mMC1R than at any other receptor.  This could suggest that the polar groups are not well 
tolerated by the MC3R, MC4R or MC5R and that the DPhe structures are interacting with a 
hydrophobic pocket. Through homology modeling and mutation studies the DPhe substituent in 
the DPhe-Arg-Trp melanocortin agonist sequence and the Arg-Phe-Phe antagonist sequence are 
both predicted to interact with aromatic residues in the mMC4R binding domain52-54. It was also 
hypothesized previously that Ac-His-Arg-DPhe-Tic-NH2 scaffold’s mixed pharmacology is caused 
by the scaffold being a hybrid between the tripeptide AgRP  sequence, “Arg-Phe-Phe” and the 
melanocortin agonist signal sequence “His-Phe-Arg-Trp”37. It could be possible that this group of 
tetrapeptides also binds in the same pocket, and hence more polar hydrophilic groups would have 
less activity.  
Hydrophobic Substitutions 
 Hydrophobic groups such as the tetrapeptides with DBip (1), p-tBu (2) and p-Me (5) 
substitutions, experienced a range of mMC3R EC50 values (13 nM < EC50 < 110 nM) (Figure 2B). 
The bulkier groups of compound 1 and 2 are 8-fold more potent at the mMC3R compared to 
compound 5. The most potent mMC3R hydrophobic substitutions are sterically bulky. Compounds 
1 and 2, containing substitutions DBip, and p-tBu, respectively, are 6.8-fold more potent at the 
mMC3R compared to the p-Me substitution. At the mMC4R all of the compounds possessing 
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hydrophobic substitutions were antagonists, mMC4R antagonism potency tends to increase when 
agonist potency at mMC3R increases. All hydrophobic groups except compound 2 show partial 
agonist activity at the mMC4R (Figure 3B).  
Electrostatics  
 The electrostatics of the tetrapeptides were studied due to trends seen in halogen data 
series51. Computational modeling for a similar tetrapeptide SAR has previously allowed for the 
study between biophysical properties and ligand-receptor interactions by modeling data from a 
halogen series 51. In Figure 6, it can be seen that the compounds that had the lowest potency at the 
mMC3R (Figure 6B) quite consistently have a larger build-up of negative charge at the DPhe 
substituent than the higher potency agonists at the mMC3R (Figure 6A).  Each of the compounds 
in Figure 6B, 8 (p-F),  9 (p-CN), and 10 (p-OH), have an electronegative atom which is 
surrounded by many more electropositive atoms, this creates a dipole giving a partial negative 
charge on the surface of the molecules. This dipole effect is muted in other tetrapeptides due to 
numerous factors such as reduced electronegativity and increased symmetry between dipoles in 
the substituents of the other tetrapeptides. Less electronegative substitutions, such as the p-I, p-
tBu, and DBip, were greater than 28-fold more potent at the mMC3R as compared to the para-
fluoro substitution. Compound 4 has a p-CF3 substituent and is 5-fold more potent than the p-F 
containing compound. While fluorine is extremely electronegative, the fluorine atoms in 
compound 4 are organized around the carbon in a symmetrical fashion canceling out each of their 
individual dipoles. However, the electrostatic interactions in the low nanomolar potency mMC3R 
agonists varies, therefore electrostatics is not sufficient to fully explain the trends seen in 
mMC3R potency.  
Halogen Substitutions: Electronegativity and Lipophilicity 
The electrostatic results match the trends seen in the halogen series, which show that the 
more electronegative the halogen, the lower the potency at the mMC3R. The trend in 
electronegativity is as follows: F > 3,4-diCl > Cl > Br > I. Potency in the mMC3R is the reverse of 
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the electronegativity trend, where the p-I ligand is the most potent halogen and the p-F compound 
is the least potent halogen (Figure 2). The antagonist activity at the mMC4R is only seen in the 
control ligand and the (3,4)-diCl compound (Figure 4 and 5). Both mMC3R and mMC4R activity 
seem to rely on electronegativity. However, there is also no statistical difference between the 
mMC3R agonist or mMC4R antagonist activity of the compound with a p-CF3 (4) substitution and 
the compound with a p-CH3 (5) substitution. This shows that electronegativity is not the only factor 
influencing the trends seen in mMC3R or mMC4R antagonist activity. 
One of the other trends that was explored was that of lipophilicity. Lipophilicity increases 
as follows: F < Cl < Br < CF3 < I < 3,4-diCl. The potency at the mMC3R data weakly supports a 
trend in lipophilicity: a more lipophilic substitution resulted in higher potency at the mMC3R 
(Table 2). However, the (3,4)-diCl containing compound (7) is not as potent as the control 
tetrapeptide containing p-I. There is a non-significant trend seen that logPoct/water was more negative 
as potency at the mMC3R went down (Figure 7). LogPoct/water values were calculated as 
QPLogPoct/water values using Maestro QikProp tool (Table 4). 
Selectivity 
 The SAR presented created more selective tetrapeptides over the mMC4R that eliminated 
much of the mMC4R agonist and antagonist activity in previous tetrapeptides while keeping low 
nanomolar potency at the mMC3R. Three new compounds containing: (3,4)-diCl, DBip, and p-
tBu, were found to be equipotent at the mMC1R, mMC3R and mMC5R compared to Ac-His-Arg-
(pI)DPhe-Tic-NH2. Compound 2 (p-tBu) was of interest because it is the most selective for the 
mMC3R over the mMC4R. This compound showed no notable agonist activity at the mMC4R and 
the mMC4R antagonist activity is at micromolar affinity compared to the low nanomolar agonist 
potency at the mMC3R.  In general, as a compound becomes more potent at the mMC3R it also 
becomes a more potent antagonist at the mMC4R (Table 2). For this reason, compound 3 (p-Br) 
was of interest because it still contains nanomolar potency at the mMC3R but it has no measurable 
antagonist mMC4R activity.  
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The DPhe substituent correlates with mMC4R agonist activity as seen by lipophilicity 
trends in the halogen series, however it is likely that there are other factors influencing mMC4R 
activity that have not been covered in this study. In order to study trends in mMC4R activity more 
thoroughly, SAR at the Arg postion of the His-Arg-(pI)DPhe-Tic compound could be completed.  
While trends in mMC4R agonist activity and antagonist activity were not significant in this 
study, the DPhe substituent contributes to mMC3R activity as seen by trends in steric interactions, 
lipophilicity and electrostatics. The mMC3R nanomolar agonist and mMC4R partial 
agonist/antagonist pharmacological profile is unique to the scaffold His-Arg-DPhe-Tic, explored 
in the TaMALES library. The His-Arg-DPhe-Tic scaffold reverses the order of the DPhe and Arg 
residues found in the common melanocortin agonist scaffold: His-DPhe-Arg-Trp. When the DPhe 
position of the His-DPhe-Arg-Trp scaffold was explored through SAR, compounds with mMC4R 
agonist activity and mMC3R partial agonist/antagonist activity were found51. This evidence 
supports the importance of the position of the DPhe residue in the His-Arg-DPhe-Tic scaffold for 
mMC3R selectivity over the mMC4R. 
Conclusions 
  The SAR presented created a more selective tetrapeptides that eliminated much of the 
mMC4R agonist and antagonist activity while keeping low nanomolar potency at the mMC3R. The 
compounds are not truly selective for mMC3R due to their activity at the mMC1R and mMC5R. 
We propose that a combination of electrostatic properties, lipophilicity and steric factors contribute 
to making more potent mMC3R agonists. These compounds can be used to further investigate the 
physiological role of the MC3R and determine if it is a worthwhile drug target for treating metabolic 
diseases.  
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Table 1. Tetrapeptide Characterizationa 
Compound Sequence 
Observed 
Mass [M+1] 
(g/mol) 
Calculated 
Exact Mass 
(g/mol) 
Purity 
(%) 
Retention 
Time in 
Acetonitrile       
(min) 
Retention 
Time  in 
Methanol 
(min) 
- Ac-His-DPhe-Arg-Trp-NH2 686.4 685.3 > 98 10.11 15.60 
- Ac-His-Arg-DPhe(p-I)-Tic-NH2 785.3 784.2 > 98 14.89 21.77 
1 Ac-His-Arg-(4,4')DBip-Tic-NH2 735.5 734.3 > 96 16.66 25.89 
2 Ac-His-Arg-DPhe(p-tBu)-Tic-NH2 715.4 714.4 > 95 17.46 27.04 
3 Ac-His-Arg-DPhe(p-Br)-Tic-NH2 737.3, 739.3 736.3, 738.3 > 97 14.89 26.07 
4 Ac-His-Arg-DPhe(p-CF3)-Tic-NH2 727.5 726.7 > 97 15.00 23.38 
5 Ac-His-Arg-DPhe(p-Me)-Tic-NH2 673.5 672.4 > 98 14.31 22.34 
6 Ac-His-Arg-DPhe(p-Cl)-Tic-NH2 693.5 692.3 > 98 14.61 22.70 
7 Ac-His-Arg-(3,4-diCl)DPhe-Tic-NH2 727.4 726.3 > 98 15.60 23.98 
8 Ac-His-Arg-DPhe(p-F)-Tic-NH2 677.5 676.3 > 95 13.55 20.82 
9 Ac-His-Arg-DPhe(p-CN)-Tic-NH2 684.3 683.3 > 98 11.50 17.25 
10 Ac-His-Arg-DTyr-Tic-NH2 675.4 674.3 > 97 10.49 15.03 
aThe pure compounds were characterized analytically using RP-HPLC with two solvent systems. Both acetonitrile and methanol 10-90% 
gradients were run in 0.1%TFA in water for 35 min. By integrating the area under the curve at 214 nm purity was determined for each 
compound. The mass was confirmed using ESI/TOF-MS  
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Table 2.  Agonist and Antagonist Activity of DPhe Substitutions at the mMC3R, mMC4R and mMC5Ra 
# Sequence 
mMC3R 
Agonist               
EC50 ± SEM 
(nM) 
Fold 
mMC4R mMC5R  
Agonist               
EC50 ± SEM 
(nM) 
Agonist 
EC50 ± SEM (nM) 
Antagonist 
pA2 ± SEM 
NDP-
MSH 
Ac-Ser-Tyr-Ser-Nle-Glu-His-DPhe-Arg-
Trp-Lys-Pro-Val-NH2 
0.42 ± 0.02 - 0.32 ± 0.03 - 0.9 ± 0.2 
- Ac-His-DPhe-Arg-Trp-NH2 190 ± 40 - 12 ± 3 - 4.3 ± 2 
- Ac-His-Arg-DPhe-Trp-NH2 1300 ± 300 - 3000 ± 1000 - 150 ± 60 
- Ac-His-Arg-DPhe(p-I)-Tic-NH2 13 ± 2 1.0 70 ± 13 (32%) 7.2 ± 0.7 4.5 ± 1 
1 Ac-His-Arg-(4,4')DBip-Tic-NH2 14 ± 2 1.1 600 ± 140 (43%) 6.1 ± 0.2 8.4 ± 0.6 
2 Ac-His-Arg-DPhe(p-tBu)-Tic-NH2 16 ± 2 1.2 > 100 µM 6.8 ± 0.3 3.3 ± 0.6 
3 Ac-His-Arg-DPhe(p-Br)-Tic-NH2 85 ± 20 6.5 230 ± 40 (54%) N/A 9.7 ± 0.5 
4 Ac-His-Arg-DPhe(p-CF3)-Tic-NH2 90 ± 30 6.9 > 100 µM 6.4 ± 0.2 13 ± 4 
5 Ac-His-Arg-DPhe(p-Me)-Tic-NH2 110 ± 20 8.5 390 ± 90 (46%) 6.3 ± 0.2 14 ± 4 
6 Ac-His-Arg-DPhe(p-Cl)-Tic-NH2 140 ± 20 11 380 ± 50 (63%) N/A 19 ± 6 
7 Ac-His-Arg-(3,4-diCl)DPhe-Tic-NH2 250 ± 40 19 > 100 µM 6.23 ± 0.06 70 ± 6 
8 Ac-His-Arg-DPhe(p-F)-Tic-NH2 450 ± 70 35 560 ± 60 (69%) N/A 5 ± 4 
9 Ac-His-Arg-DPhe(p-CN)-Tic-NH2 4000 ± 1000 308 29% @ 100 µM N/A 500 ± 200 
10 Ac-His-Arg-DTyr-Tic-NH2 4300 ± 800 331 > 100 µM N/A 1200 ± 600 
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aData summary from colorimetric assay that gives a signal proportional to increases in cAMP. Data was collected from three independently 
conducted experiments, each with duplicate replicates. NDP-MSH,Ac-His-DPhe-Arg-Trp-NH2, and forskolin were all used as positive 
controls. Adenylate cyclase is activated by forskolin independently of the melanocortin system. Assay media was used as a negative control. 
Activity for partial agonists is recorded as an EC50 value followed by the percentage of NDP-MSH maximum activation of the receptor at 
100 µM in parenthesis. Activity for less than full agonists is denoted as a percentage of NDP-MSH maximal activation of the receptor. 
Compounds with less than 20% activity compared to maximal percent activation of NDP-MSH are recorded as EC50 > 100000 nM. 
Antagonist activity was tested using NDP-MSH as an agonist and ligand concentrations of: 10000, 5000, 1000, and 500nM. Dose dependent 
shifts in EC50 enables the calculation of a pA2 value determined by Schild analysis55. If no shift is detected in the antagonist experiment, 
the outcome is denoted by “N/A” meaning there is no activity observed up to 10uM. Fold values were calculated in comparison to the 
mMC3R potency of c-His-Arg-DPhe(p-I)-Tic-NH2.  
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Table 3.  Agonist Activity of DPhe Substitutions at the mMC1Ra 
Compound Sequence 
mMC1R 
Agonist 
EC50 + SEM (nM) 
NDP-MSH Ac-Ser-Tyr-Ser-Nle-Glu-His-DPhe-Arg-Trp-Lys-Pro-Val-NH2 0.012 ± 0.002 
- Ac-His-DPhe-Arg-Trp-NH2 10 ± 4 
- Ac-His-Arg-DPhe(p-I)-Tic-NH2 0.8 ± 0.3 
1 Ac-His-Arg-(4,4')DBip-Tic-NH2 0.52 ± 0.03 
2 Ac-His-Arg-DPhe(p-tBu)-Tic-NH2 10 ± 3 
3 Ac-His-Arg-DPhe(p-Br)-Tic-NH2 0.8 ± 0.3 
4 Ac-His-Arg-DPhe(p-CF3)-Tic-NH2 6 ± 2 
5 Ac-His-Arg-DPhe(p-Me)-Tic-NH2 1.2 ± 0.3 
6 Ac-His-Arg-DPhe(p-Cl)-Tic-NH2 0.95 ± 0.08 
7 Ac-His-Arg-(3,4-diCl)DPhe-Tic-NH2 6 ± 2 
8 Ac-His-Arg-DPhe(p-F)-Tic-NH2 2.2 ± 0.7 
9 Ac-His-Arg-DPhe(p-CN)-Tic-NH2 32 ± 3 
10 Ac-His-Arg-DTyr-Tic-NH2 50 ± 10 
a Data summary from intracellular cAMP readings using AlphaScreen (PerkinElmer). Data was collected from three independently 
conducted experiments, each with duplicate replicates. NDP-MSH, Ac-His-DPhe-Arg-Trp-NH2, and forskolin were all used as 
positive controls. Adenylate cyclase is activated by forskolin independently of the melanocortin system. Assay media was used 
as a negative control.  
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Table 4. Calculated Properties of Tetrapeptides  
Entry ID Substitution 
MC3R 
Agonist 
Activity 
(EC50  nM) 
Portential 
Energy-OPLS-
2005 
(KJ/mol) 
Hydrogen Bond 
Donors 
Hydrogen Bond 
Acceptors 
Polarizability 
(Å3) logPo/w 
Polar Surface 
Area (Å) 
KNS2224 pI 13 -862 7.75 14.25 64 -0.399 266 
KNS2231 DBip 14 -875 7.75 14.25 69 0.505 253 
KNS2233 ptBu 16 -924 7.75 14.25 72 0.665 267 
KNS2223 pBr 85 -856 7.75 14.25 62 -0.223 252 
KNS2236 pCF3 90 -866 7.75 14.25 64 -0.649 266 
KNS2237 pCH3 110 -872 7.75 14.25 70 -0.355 269 
KNS2221 pCl 140 -776 7.75 14.25 68 0.019 269 
KNS2234 (3,4,)diCl 250 -829 7.75 14.25 67 -0.121 270 
KNS2222 pF 450 -778 7.75 14.25 67 -0.205 273 
KNS2238 pCN 4000 -872 7.75 15.75 65 -1.034 290 
KNS2239 pOH 4300 -893 8.75 15 67 -1.235 291 
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              Ac-His-Arg-XXX-Tic-NH
2  
 
 
 
 
 
 
 
 
Tetrapeptide Melanocortin Agonist 
Ligands to Explore Selectivity  
(TaMALES) Library 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
R1 
Figure 1. TaMALES library scaffold and the amino acid side chains used in the peptide library.  
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Figure 2. Illustration of agonist activity observed mouse melanocortin-3 receptor. A) Halogen series of substitutions with the Ac-His-Arg-
(pI)DPhe-Tic-NH2 control annotated as p-I. B) Hydrophobic series of substitutions. C) The Ac-His-Arg-(pI)DPhe-Tic-NH2 control annotated 
as pI, the methyl substituent, p-CF3 substituent, and the two substituents with micromolar potency (p-CN and p-OH substituent).  
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Figure 3. Illustration of agonist activity observed mouse melanocortin-4 receptor. A) Halogen series of substitutions with the Ac-His-Arg-
(pI)DPhe-Tic-NH2 control annotated as p-I. B) Hydrophobic series of substitutions. C) The methyl substituent, p-CF3 substituent, and the two 
substituents with micromolar potency (p-CN and p-OH substituents).  
B) 
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Figure 4. Illustration of antagonist activity observed at the mouse melanocortin-4 receptor from 
the most potent-MC3R agonists. A) Illustration of mMC4R antagonist data from the control 
peptide: Ac-His-Arg-(pI)DPhe-Tic-NH2. . B) Depiction of mMC4R antagonist data from Ac-
His-Arg-DBip-Tic-NH2. C) Depiction of mMC4R antagonist data from Ac-His-Arg-(p-
tBu)DPhe-Tic-NH2.. The pA2 values are calculated using Schild analysis. The pA2 = -Log(Ki).  
A) 
C) 
B) 
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Figure 5. Illustration of antagonist activity observed at the mouse melanocortin-4 receptor.A) 
Illustration of mMC4R antagonist data from the control peptide: Ac-His-Arg-(pCF3)DPhe-
Tic-NH2. . B) Depiction of  mMC4R antagonist data from Ac-His-Arg-(pCH3)DPhe-Tic-NH2. 
C) Depiction of mMC4R antagonist data from Ac-His-Arg-(3,4)-dicl)DPhe-Tic-NH2.. The pA2 
values are calculated using Schild analysis. The pA2 = -Log(Ki).  
A) 
C) 
B) 
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Figure 6. Electrostatic potentials calculated with Maestro. Red represents electronegative  (-5.5 kT/e), blue represents electropositive (+5.5 kT/e). 
The molecule is oriented with the histidine residue facing upwards on the left hand side, the arginine is in the bottom left corner, the 
DPhenylalanine substitutions are facing upward on the right hand side and the Tic residue is in the bottom right corner. The DPhenylalanine 
substitutions is circled in black on the first compound. The upper A) Low nanomolar potency mMC3R compounds including: compound 1, 2  and 
the control para iodo compound. B) Micromolar potency mMC3R compounds including: compound 8, 9, and 10.
Ac-His-Arg-DPhe(pI)-Tic-NH2 A) DBip: Compound 1 
p-tBu: Compound 2 
p-F: Compound 8 p-CN: Compound 9 
p-OH: Compound 10 
B)  
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Figure 7. A scatterplot showing the potential trend between partition coefficient of octenol over 
water and mMC3R EC50 values. The x-axis is on a logarithmic scale. LogPo/w values were 
calculated in Maestro. There is a slight trend when logPo/w values go down the EC50 also 
decreases. The trend is not statistically significant, when it is fit with logarithmic regression line 
the R2 value is 0.6866.  
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